OR WAIT null SECS
Bio-Rad has launched a range of antibodies specifically for daratumumab that inhibit the binding of the drug to the target antigen, CD38, which allows for highly specific bioanalysis and drug monitoring.
Bio-Rad Laboratories launched a range of anti-daratumumab antibodies that are specific for daratumumab (Darzalex) in February 2022. These antibodies inhibit the binding of daratumumab to its target, CD38. Because of their high specificity and high-affinity these recombinant antibodies are suitable for bioanalysis and drug monitoring of daratumumab and its biosimilars.
Bio-Rad’s portfolio of antibodies are generated using the Human Combinatorial Antibody Libraries and CysDisplay, a proprietary method of phage display, along with guided selection methods to obtain highly targeted reagents, according to the company in a Feb. 14, 2022 press release. The anti-daratumumab antibodies are approved for in-vitro research purposes and for commercial applications providing in-vitro testing services to support preclinical and clinical drug development.
Daratumumab, an anticancer drug that binds to the CD38 protein that is overexpressed in multiple myeloma cells, leads to immune-mediated apoptosis of the tumor cell. The new range of anti-daratumumab antibodies comprises three fully human immunoglobulin G1 inhibitory antibodies that have varying levels of affinity. The antibodies can be used as surrogate positive controls in anti-drug antibody assays as well as for the development of pharmacokinetic bridging enzyme-linked immunoassays to measure free drug.
“We are pleased to continue the expansion of our range of anti-idiotypic antibodies to support researchers developing novel treatments,” said Amanda Turner, Bio-Rad product manager, Life Science Group, in the press release. “Our recombinant production methods result in batch-to-batch consistency, so researchers can rely on our antibodies to deliver reproducible results over the lifecycle of their bioanalytical assays.”